Half Year 2026 Dr Reddy's Laboratories Ltd Earnings Call Transcript

Oct 24, 2025 / 02:00 PM GMT

Release Date Price: €12.5

Transcript

Key Points

Positve

Dr Reddy's Laboratories Ltd (RDY) reported a consistent performance in Q2 FY26, marked by a double-digit growth and steady profitability.
The company achieved a 9.8% year-over-year revenue growth, supported by the integration of the consumer healthcare business and favorable foreign exchange rates.
The India business delivered a double-digit year-on-year growth of 13%, driven by new product launches, improved pricing, and higher volumes.
Dr Reddy's Laboratories Ltd (RDY) made significant progress in its strategic priorities, including growing its base, scaling presence in consumer healthcare, and advancing key pipeline programs.
The company maintained a strong balance sheet with a net cash surplus of $310 million, reinforcing financial stability.

Negative

The US generics business faced pressure from product-specific price erosion and lower sales, impacting overall performance.
Consolidated gross profit margin decreased by 492 basis points year-over-year due to lower sales and price erosion in the US generics market.
The company experienced a one-time inventory write-off due to the discontinuation of certain pipeline products, affecting margins.
There were regulatory challenges, including a complete response letter from the US FDA for the rituximab biosimilar candidate, requiring further action.
The North America business reported a revenue decline of 16% year-on-year, primarily due to price erosion in key products.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

REDY.NS - Dr Reddy's Laboratories Ltd
Half Year 2026 Dr Reddy's Laboratories Ltd Earnings Call
Oct 24, 2025 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day.

And welcome to quarter to, fiscal year 2012.

Tres Limited. I'm Aishwaraitaram and I'm part of the Doctor Ed's investor relations team. I'd like to indicate that all participants will be in the listen-only mode during the opening remarks, and there will be an opportunity for you to ask questions thereafter.

Should you need any technical assistance during the call, please use the chat function in your Zoom application.

Please note that the chat will not be monitored for any questions to the management. I now hand over the conference to Richa Perival.

Thank you.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.